These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 37995863)
1. Oncological characteristics of epidermal growth factor receptor-mutated clinical stage IA lung adenocarcinoma with radiologically pure-solid appearance. Hattori A; Matsunaga T; Fukui M; Tomita H; Takamochi K; Suzuki K J Thorac Cardiovasc Surg; 2024 Sep; 168(3):685-696.e2. PubMed ID: 37995863 [TBL] [Abstract][Full Text] [Related]
2. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features. Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156 [TBL] [Abstract][Full Text] [Related]
3. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer. Watanabe Y; Hattori A; Nojiri S; Matsunaga T; Takamochi K; Oh S; Suzuki K J Thorac Cardiovasc Surg; 2022 Mar; 163(3):791-801.e4. PubMed ID: 33516459 [TBL] [Abstract][Full Text] [Related]
4. Impact of a Ground-glass Opacity Component on c-Stage IA Lung Adenocarcinoma. Li M; Xi J; Sui Q; Kuroda H; Hamanaka K; Bongiolatti S; Hong G; Zhan C; Feng M; Wang Q; Tan L Semin Thorac Cardiovasc Surg; 2023 Winter; 35(4):783-795. PubMed ID: 35907612 [TBL] [Abstract][Full Text] [Related]
5. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity. Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of CT-defined ground-glass opacity in early-stage lung adenocarcinomas: a single-center study and meta-analysis. Lee JH; Choi Y; Hong H; Kim YT; Goo JM; Kim H Eur Radiol; 2024 Mar; 34(3):1905-1920. PubMed ID: 37650971 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer. Hattori A; Suzuki K; Takamochi K; Wakabayashi M; Aokage K; Saji H; Watanabe SI; J Thorac Cardiovasc Surg; 2021 Apr; 161(4):1469-1480. PubMed ID: 32451073 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component. Xu Y; Zheng M; Wang N; Wang R Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020 [TBL] [Abstract][Full Text] [Related]
9. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma. Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010 [TBL] [Abstract][Full Text] [Related]
10. Evaluating the necessity of lymph node sampling in lung adenocarcinoma with ground glass opacities. Li H; Wu Y; Gao S; Zhou Y; Yang R; Wu Y Surgery; 2024 Sep; 176(3):927-933. PubMed ID: 38879379 [TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma. Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179 [TBL] [Abstract][Full Text] [Related]
12. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma. Yang F; Sun K; Li F; Li X; Shi J; Sun X; Hong Y; Jiang G; Zhu Y; Song X Ann Thorac Surg; 2024 Jun; 117(6):1111-1119. PubMed ID: 37353101 [TBL] [Abstract][Full Text] [Related]
13. A Proposal for Restaging of Invasive Lung Adenocarcinoma Manifesting as Pure Ground Glass Opacity. Mao R; She Y; Zhu E; Chen D; Dai C; Wu C; Xie H; Zhu H; Fei K; Chen C Ann Thorac Surg; 2019 May; 107(5):1523-1531. PubMed ID: 30576635 [TBL] [Abstract][Full Text] [Related]
14. Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival. Berry MF; Gao R; Kunder CA; Backhus L; Khuong A; Kadoch M; Leung A; Shrager J Clin Lung Cancer; 2018 Jan; 19(1):e47-e51. PubMed ID: 28743420 [TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer. Kamigaichi A; Tsutani Y; Mimae T; Miyata Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M Eur J Cardiothorac Surg; 2022 Aug; 62(3):. PubMed ID: 35293580 [TBL] [Abstract][Full Text] [Related]
16. Prognostic influence of a ground-glass opacity component in hypermetabolic lung adenocarcinoma. Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K Eur J Cardiothorac Surg; 2022 Jan; 61(2):249-256. PubMed ID: 34632486 [TBL] [Abstract][Full Text] [Related]
17. Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules. Fu F; Zhang Y; Wang S; Li Y; Wang Z; Hu H; Chen H J Thorac Cardiovasc Surg; 2021 Aug; 162(2):451-459.e3. PubMed ID: 32711984 [TBL] [Abstract][Full Text] [Related]
18. What is the radiological definition of part-solid tumour in lung cancer?†. Matsunaga T; Suzuki K; Takamochi K; Oh S Eur J Cardiothorac Surg; 2017 Feb; 51(2):242-247. PubMed ID: 28119328 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non-Small Cell Lung Cancer. Hattori A; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K J Thorac Oncol; 2017 Jun; 12(6):954-962. PubMed ID: 28257958 [TBL] [Abstract][Full Text] [Related]
20. Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma. Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1100-1108. PubMed ID: 28629842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]